v3.22.2
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net loss $ (5,288) $ (5,137)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 31 39
Stock-based compensation 26 38
Non-cash lease expense 2 13
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (87) (515)
Accounts payable 433 169
Accrued expenses 218 327
Accrued compensation expenses (70) 234
Accrued clinical trial expenses (462) (131)
Net cash used in operating activities (5,197) (4,963)
Cash flows from investing activities:    
SAFE (see Note 1) (8,000)
Purchases of property and equipment (18)
Net cash used in investing activities (8,018)
Cash flows from financing activities:    
Net proceeds from sale of common stock and exercise of warrants 77,814
      Repayment of debt (2,200)
Net cash provided by financing activities 75,614
Effect of exchange rate changes on cash and cash equivalents (1) 17
Cash and cash equivalents:    
Net increase (decrease) (13,216) 70,668
Balance at beginning of period 69,593 3,177
Balance at end of period 56,377 73,845
Cash paid during the period ended for:    
Interest $ 135

Source